Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivipansel PK in Hepatic Impairment
NCT02871570Phase 1Completed
- Sponsor
- GlycoMimetics
- Start
- Sep 2016
- Primary completion
- Feb 2017
- Modality
- Bivalent/Multivalent Binders, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivipansel in sickle cell disease (SCD) (2 arms), sponsored by GlycoMimetics. Primary endpoints: Number of Participants With Post-baseline Clinically Significant Findings in Physical Examinations at Day 5, Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and 5 more. Started Sep 2016; status: completed.
02
Drugs
rivipansel
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02871570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871570.